PHVS Pharvaris
- 23.530
- -1.040-4.23%
Pharvaris News
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 417.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 23, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 20,000 shares of its common stock on Apr 23, with a total market value of approximately $417.4K. MORGAN CONN
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $34.00 to $34.00.
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $34.00 to $34.00.
Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and maintains $34 price target.
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 311.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 14,242 shares of its common stock on Apr 15, with a total market value of approximately $311.9K. Source: Ann
Pharvaris Is Maintained at Overweight by Morgan Stanley
Pharvaris Is Maintained at Overweight by Morgan Stanley
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $35.00 to $34.00.
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $35.00 to $34.00.
Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
Morgan Stanley analyst Matthew Harrison maintains Pharvaris with a Overweight and lowers the price target from $35 to $34.
Pharvaris Shares Are Trading Lower After the Company Filed for a Mixed Shelf Offering.
Pharvaris Shares Are Trading Lower After the Company Filed for a Mixed Shelf Offering.
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
Pharvaris Files for Automatic Mixed Securities Shelf
Pharvaris NV Files For Mixed Shelf Offering; Size Not Disclosed
Pharvaris NV Files For Mixed Shelf Offering; Size Not Disclosed
Pharvaris N.V.'s High-Stakes Gamble: Navigating Clinical Trials and Regulatory Hurdles for Market Success
Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials
Pharvaris Is Maintained at Market Outperform by JMP Securities
Pharvaris Is Maintained at Market Outperform by JMP Securities
Pharvaris Price Target Raised to $50.00/Share From $49.00 by JMP Securities
Pharvaris Price Target Raised to $50.00/Share From $49.00 by JMP Securities
Wedbush: Reiterates the Pharvaris (PHVS.US) rating and adjusted from superior to superior market rating, with a target price of $35.00.
Wedbush: Reiterates the Pharvaris (PHVS.US) rating and adjusted from superior to superior market rating, with a target price of $35.00.
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
Pharvaris Excels in HAE Treatment Advances
Buy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial Stability
Pharvaris Narrows Q4 Net Loss; Hires New CFO
Pharvaris (PHVS) late Wednesday reported a Q4 net loss of 0.74 euros ($0.80) per diluted share, compared with a 1.16 euro loss a year earlier. Analysts polled by Capital IQ expected a 0.57 loss. As ex
Analysis
Price Target
No Data
